Investment analysts at Leerink Partnrs increased their Q4 2024 earnings estimates for shares of Regeneron Pharmaceuticals in a research report issued on Tuesday, January 28th. Leerink Partnrs analyst ...
Shares of Regeneron Pharmaceuticals Inc. REGN slipped 1.48% to $672.98 Friday, on what proved to be an all-around grim ...
Zacks.com on MSN20h
Regeneron to Report Q4 Earnings: Is a Beat in the Cards?Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, 2025. The Zacks Consensus Estimate for fourth-quarter revenues is pegged at ...
All the latest breaking local news from Limerick and County Limerick Please allow ads as they help fund our trusted local ...
Hosted on MSN23h
Ahead of Regeneron (REGN) Q4 Earnings: Get Ready With Wall Street Estimates for Key MetricsThe upcoming report from Regeneron (REGN) is expected to reveal quarterly earnings of $11.60 per share, indicating a decline of 2.2% compared to the year-ago period. Analysts forecast revenues of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback